1st Quarter 2022 Results

Worldwide Sales Increased 5.0% to $23.4B
Excluding acquisitions/diestuities on an operational basis

Diluted Earnings Per Share
Decreased (16.8) to $1.93
Adjusted Diluted Earnings Per Share
Increased 3.1% to $2.67

"Our first quarter results demonstrate strong performance across the enterprise, despite macro-economic headwinds. I am incredibly proud of Johnson & Johnson’s 144,000 employees for their relentless passion and Credo-based commitment to delivering transformative healthcare solutions to patients and customers around the world. Looking ahead, I remain confident in the future of Johnson & Johnson as we continue advancing our portfolio and innovative pipeline."

Joaquin Duato
Chief Executive Officer
Johnson & Johnson

Worldwide Consumer Health Sales:
Consumer Health worldwide reported sales decreased (5.9%), but increased 0.8% operationally, Primary operational drivers:

- $3.6 Billion
- Tylenol
- Zyrtec
- Motrin
- Imodium
- Benadryl
- Lubriderm

Worldwide Pharmaceutical Sales:
Pharmaceutical worldwide reported sales increased 6.3% or 9.3% operationally, Primary operational drivers:

- $12.9 Billion
- Stelara
- Darzalex
- Tremfya
- Erleada
- Upjohn
- Invega Sustenna

Worldwide MedTech Sales:
MedTech worldwide reported sales increased 6.9% or 8.5% operationally, Primary operational drivers:

- $7.0 Billion
- Electrophysiology
- Contact Lens
- Wound Closure
- Surgical Vision
- Hip

Note: values may have been rounded; the MedTech segment was previously referred to as the Medical Devices segment.


Non-GAAP financial measures, non-GAAP financial measures should not be considered replacements for, and should be read together with, the most comparable GAAP financial measures.

Free-OF-OTC products, primarily in China, were reclassified from the Pharmaceutical segment to the Consumer Health segment based on operational changes in those respective regions.

Caution Concerning Forward-Looking Statements: This document contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995 regarding future operating and financial performance. The forward-looking statements are based on certain assumptions and estimates which can be affected by various risks and uncertainties which are beyond our control and which could cause actual results to vary materially from the assumptions, expectations, and projections expressed in any forward-looking statements. Readers are referred to "Risk Factors" included in the Johnson & Johnson’s earnings release based on April 19, 2022, as well as to the most recently filed Johnson & Johnson Reports on Forms 10-K and 10-Q. Johnson & Johnson does not undertake to update any forward-looking statement as a result of any new information or future events or developments.